格隆汇12月29日丨巨子生物(02367.HK)公告，12月29日耗资1381.4万港元回购40万股，每股回购价 34.28-34.76港元。 ...

呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月23日 | 1 ...

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 18.48%, 16.79%, and 15.54% respectively [1][2] - The companies with the largest absolute increase in short positions are CATL (03750), Lens Technology (06613), and UBTECH Robotics (09880), which increased by 2.35%, 2.34%, and 1.29% respectively [1][2] - The companies with the largest absolute decrease in short positions are Changfei Optical Fiber (06869), Mao Ge Ping (01318), and Meilan Airport (00357), which decreased by -1.26%, -0.68%, and -0.67% respectively [1][2] Group 2 - The latest short ratio for Vanke Enterprises (02202) is 18.48%, down from 19.04% previously [3] - The latest short ratio for COSCO Shipping Holdings (01919) is 16.79%, down from 16.79% previously [2] - The latest short ratio for Heng Rui Medicine (01276) is 15.54%, up from 3919.30 million shares to 4011.67 million shares [2]

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The "Jizhi Award" was announced, with Juzhi Biotechnology winning the "Outstanding Growth Enterprise" award, aimed at setting high-quality development benchmarks and guiding listed companies to focus on their main business and continuous innovation [2][3] Company Performance - Juzhi Biotechnology demonstrated strong growth resilience in a sluggish market, achieving a revenue of 3.113 billion yuan in the first half of 2025, a year-on-year increase of 22.52%, and a net profit of 1.182 billion yuan, up 20.23% [4] - The company's main business focuses on professional skincare products and health foods, with professional skincare products accounting for over 99% of its core revenue [4] Brand Performance - The flagship brand, Kefu Mei, generated 2.54 billion yuan in revenue in the first half of 2025, a 22.7% increase, representing 81.7% of total revenue, with key products performing well in major sales events [5] - The Keli Jin brand also showed strong performance with a revenue of 503 million yuan, up 26.9%, and its star product ranked in the top 4 of the Tmall sales list for facial masks [5] Future Outlook - Juzhi Biotechnology plans to continue focusing on its main business, enhancing innovation, strengthening its omnichannel layout, and expanding into medical aesthetics and overseas markets to contribute to the high-quality development of the biological skincare industry [5]

Investment Rating - Industry rating: "Accumulate" (maintained) [7] Core Insights - The approval of the cross-linked recombinant collagen implant by Chuangjian Medical on December 23, 2025, marks a significant addition to the recombinant collagen industry, which is expected to expand further [7] - Lin Qingxuan has passed the Hong Kong Stock Exchange listing hearing, potentially becoming the first high-end domestic skincare stock in Hong Kong [7] - The "oil-based skincare" brand Afu released the industry's first technical standard for functional skincare products on December 8, 2025, supporting the standardized development of the "oil-based skincare" sector [7] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -21.5% compared to the CSI 300 index, with absolute returns of -4.52% [3] Key Events - Chuangjian Medical's recombinant collagen implant is composed of cross-linked recombinant collagen hydrogel and is approved for facial dermal filling to correct moderate to severe dynamic wrinkles [7] - Lin Qingxuan's core product, camellia oil essence, has seen its revenue share increase from 31.5% in 2022 to an expected 45.5% in the first half of 2025, maintaining its position as the top-selling facial essence oil in China for 11 consecutive years [7] Investment Recommendations - The successful approval of Chuangjian Medical's product is expected to enhance industry growth, with a recommendation to monitor the product's market performance post-launch [7] - The sales of essence oils across major online platforms are projected to exceed 9.5 billion yuan from March 2024 to February 2025, with facial essence oils experiencing a 36% growth, indicating a strong market demand [7]

Summary of Conference Call on High-End Domestic Beauty Brand Growth Company Overview - The focus is on the high-end domestic beauty brand, 毛戈平, which is expected to maintain a growth rate of 25%-30% over the next two years due to membership operations and product category iteration [1][4]. Core Industry Insights - The beauty industry can be categorized into three types of companies: 1. Companies like 珀莱雅 that capitalized on e-commerce demand from 2015 to 2021 through rapid product iterations. 2. Companies like 巨子生物 that leveraged structural category trends for product innovation. 3. 毛戈平, which relies on service-driven product sales and has built a loyal customer base through high-quality service [2]. Key Growth Drivers - **Membership Operations**: 毛戈平's membership system is crucial, with approximately 10% of loyal members contributing over 70% of revenue [5][8]. - **Online and Offline Synergy**: The online channel not only generates revenue but also drives traffic to offline stores. In 2025, over 75% of new customers came from online channels, with 25%-30% converting to offline customers [6][8]. - **Product Strategy**: The brand focuses on driving repurchase of existing major products, with a projected growth rate of 40% in 2025, tapering to around 30% in subsequent years [9][10]. Long-Term Growth Potential - 毛戈平's long-term growth will depend on product category expansion, particularly in basic skincare and fragrance, which currently contribute less than 10% to revenue but have significant potential [11][12]. - The company is expected to maintain stable growth through 2026 and 2027, but substantial breakthroughs in skincare or fragrance are necessary for sustained growth beyond that [13]. Sales and Marketing Strategies - **Direct Sales Model**: 毛戈平 employs a direct sales model, focusing on online and offline sales, with a significant portion of revenue coming from direct sales [14]. - **Customer Conversion**: The brand effectively converts online users to offline customers through differentiated membership benefits and targeted marketing strategies [15][16]. - **Sales Incentives**: The company incentivizes sales personnel to enhance the conversion rate from online to offline, achieving a conversion rate of approximately 20% [17]. Unique Competitive Advantages - 毛戈平's strategy differs from other beauty brands by establishing a strong direct sales system from the outset and using a limited range of online products to drive traffic to a more extensive offline market [18]. This comprehensive approach positions 毛戈平 as a unique player in the competitive beauty market, with a focus on sustainable growth through customer loyalty and innovative product offerings.

摘要 创建公司推出交联重组胶原蛋白填充剂，采用独特 474 个氨基酸序列， 提供多种规格预灌封注射器包装，旨在与现有非交联产品及部分动物来 源胶原蛋白市场竞争，凭借即刻维持时间和形态优势，有望成为微整形 领域新选择，但市场表现需进一步观察。 业内普遍认为创建公司的交联技术成熟，安全性是关注点，消费者态度 复杂，期望长效但对潜在风险谨慎。机构推荐和安全性报告是消费者接 受的关键。该技术自主研发，已应用于疫苗等领域，关键在于杂质控制 和工艺流程管理，需持续改进生产工艺及严格质量控制。 创建公司医美团队月白知己由张笑红领导，拥有丰富的皮肤科产品代理 经验和客户资源，产品主要通过代理商渠道销售，覆盖皮肤科和部分注 射科室。未来大型连锁倾向成熟品牌，新氧倾向独家定制，中小机构倾 向低成本引流产品。 重组胶原蛋白被视为下一个潜力市场，未来将有多种类型和规格产品获 批。序列越长风险越高，需权衡序列长度与安全性。短序列在提纯和生 产中更简便，更具成本优势。非天然片段的引入主要为方便生产和降低 成本，实际效果需临床验证。 Q&A 创建公司最近获得的三型胶原蛋白证书有哪些特别之处？它在市场运营中可能 会如何定位和推广？ 创建公司 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]

来源：新浪证券 出品：新浪财经上市公司研究院 作者：喜乐 12月18日，林清轩启动港股全球发售，预计于12月30日上市。本次IPO采用定价发行，发行价为77.77港 元/股，基础发行股数约1397万股，绿鞋后发行股数约1606万股，对应发行规模约10.9-12.5亿元。作为 港股市场首个主打"本土高端护肤"定位的上市企业，林清轩的IPO不仅承载着自身的资本跃迁梦想，更 被视作观察资本市场对国货高端化价值判断的重要样本。其亮眼的业绩增长、独特的品牌定位与多元化 的资本支持，让这场上市备受瞩目，但与此同时，市场对其高端定位、竞争韧性及估值合理性的质疑也 从未停歇，这场资本盛宴背后的多重考验正逐步浮现。 深耕山茶花赛道 2025年上半年收入盈利近翻倍 林清轩自2012年起开展山茶花护肤品研究，开创"以油养肤"理念，2014年推出的首款山茶花精华油成为 核心产品。历经多年发展，林清轩旗下提供全系列高端护肤改善方案，包括精华油、面霜、爽肤水及乳 液、精华液、面膜及防晒霜，旨在支持自清洁及爽肤至保湿及针对性护肤的全套护肤流程。截至2025年 6月30日，林清轩提供230个SKU。 业绩层面，林清轩近年实现跨越式增长。20 ...